Research programme: AstraZeneca 4 Programs - AstraZeneca and Pieris Pharmaceuticals

Drug Profile

Research programme: AstraZeneca 4 Programs - AstraZeneca and Pieris Pharmaceuticals

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Pieris Pharmaceuticals
  • Developer AstraZeneca; Pieris Pharmaceuticals
  • Class Lipocalins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Respiration disorders

Most Recent Events

  • 03 May 2017 Early research in Respiration disorders in United Kingdom (Inhalation) (Pieris Pharmaceuticals Pipeline, May 2017)
  • 03 May 2017 Early research in Respiration disorders in USA (Inhalation) (Pieris Pharmaceuticals Pipeline, May 2017)
  • 03 May 2017 AstraZeneca enters into a collaboration with Pieris Pharmaceuticals for Respiratory disorders to develop Anticalin®-based inhaled treatments
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top